LT4483956T - Troriluzolo panaudojimas spinocerebralinės ataksijos 3 (sca3) gydymui - Google Patents
Troriluzolo panaudojimas spinocerebralinės ataksijos 3 (sca3) gydymuiInfo
- Publication number
- LT4483956T LT4483956T LTEP24199849.1T LT24199849T LT4483956T LT 4483956 T LT4483956 T LT 4483956T LT 24199849 T LT24199849 T LT 24199849T LT 4483956 T LT4483956 T LT 4483956T
- Authority
- LT
- Lithuania
- Prior art keywords
- troriluzole
- sca3
- treatment
- spinocerebellar ataxia
- spinocerebellar
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584856P | 2017-11-12 | 2017-11-12 | |
| US201862717948P | 2018-08-13 | 2018-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT4483956T true LT4483956T (lt) | 2026-04-27 |
Family
ID=66438598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP24199849.1T LT4483956T (lt) | 2017-11-12 | 2018-11-11 | Troriluzolo panaudojimas spinocerebralinės ataksijos 3 (sca3) gydymui |
| LTEPPCT/US2018/060232T LT3706739T (lt) | 2017-11-12 | 2018-11-11 | Riluzolo provaisto naudojimas ataksijų gydymui |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2018/060232T LT3706739T (lt) | 2017-11-12 | 2018-11-11 | Riluzolo provaisto naudojimas ataksijų gydymui |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20210023061A1 (lt) |
| EP (4) | EP4483956B1 (lt) |
| JP (2) | JP7352542B2 (lt) |
| KR (2) | KR20200103658A (lt) |
| CN (1) | CN112292127A (lt) |
| AU (1) | AU2018364749C1 (lt) |
| BR (1) | BR112020009173A2 (lt) |
| CA (1) | CA3082096A1 (lt) |
| DK (2) | DK3706739T3 (lt) |
| ES (1) | ES2996892T3 (lt) |
| FI (2) | FI4483956T3 (lt) |
| HR (1) | HRP20241675T1 (lt) |
| HU (1) | HUE070302T2 (lt) |
| IL (1) | IL274532B2 (lt) |
| LT (2) | LT4483956T (lt) |
| MD (1) | MD3706739T2 (lt) |
| MX (2) | MX2020004678A (lt) |
| PH (1) | PH12020550583A1 (lt) |
| PL (1) | PL3706739T3 (lt) |
| PT (2) | PT3706739T (lt) |
| RS (2) | RS66277B1 (lt) |
| SG (1) | SG11202004332XA (lt) |
| SI (1) | SI3706739T1 (lt) |
| SM (2) | SMT202500022T1 (lt) |
| WO (1) | WO2019094851A1 (lt) |
| ZA (1) | ZA202002626B (lt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10639298B2 (en) | 2015-03-03 | 2020-05-05 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole and their method of use |
| US12295942B2 (en) | 2015-03-03 | 2025-05-13 | Biohaven Therapeutics Ltd. | Riluzole prodrugs and their use |
| US12029731B2 (en) | 2016-08-10 | 2024-07-09 | Biohaven Therapeutics Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| WO2022155564A1 (en) * | 2021-01-18 | 2022-07-21 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
| WO2023081860A1 (en) * | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Triazine amino derivatives for treating sca3 |
| JP2025517509A (ja) * | 2022-05-23 | 2025-06-05 | バイオヘイブン・セラピューティクス・リミテッド | 脊髄小脳失調症を治療する方法 |
| WO2026078657A1 (en) | 2024-10-10 | 2026-04-16 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| WO1995001782A2 (en) | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| WO1998036738A1 (en) | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| ATE323467T1 (de) | 1997-07-25 | 2006-05-15 | Alpex Pharma Sa | Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten |
| FR2774592B1 (fr) * | 1998-02-06 | 2000-03-17 | Rhone Poulenc Rorer Sa | Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet |
| US7939105B2 (en) | 1998-11-20 | 2011-05-10 | Jagotec Ag | Process for preparing a rapidly dispersing solid drug dosage form |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| DE60222160T2 (de) | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
| EP1485296B1 (en) | 2002-02-13 | 2011-07-20 | Michael K. Weibel | Drug dose - form and method of manufacture |
| DK1477166T3 (da) * | 2003-04-28 | 2006-12-11 | Biofrontera Bioscience Gmbh | Anvendelse af riluzoler kombineret med egnede hjælpe- og tilsætningsstoffer til behandling af sygdomme, som er kendetegnet ved en hyperproliferation af keratinocytter, navnlig neurodermitis og psoriasis |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| EP1978939A2 (en) | 2005-12-27 | 2008-10-15 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine |
| EP2170282A4 (en) | 2007-06-27 | 2014-11-05 | Hanmi Pharm Ind Co Ltd | METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION |
| EP2271344A4 (en) * | 2008-03-31 | 2011-04-27 | Univ South Florida | METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE |
| US8221480B2 (en) | 2008-10-31 | 2012-07-17 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8414356B2 (en) | 2008-10-31 | 2013-04-09 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| US10639298B2 (en) * | 2015-03-03 | 2020-05-05 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole and their method of use |
-
2018
- 2018-11-11 MD MDE20200953T patent/MD3706739T2/ro unknown
- 2018-11-11 LT LTEP24199849.1T patent/LT4483956T/lt unknown
- 2018-11-11 MX MX2020004678A patent/MX2020004678A/es unknown
- 2018-11-11 KR KR1020207016775A patent/KR20200103658A/ko not_active Ceased
- 2018-11-11 KR KR1020257006278A patent/KR20250034521A/ko active Pending
- 2018-11-11 ES ES18876779T patent/ES2996892T3/es active Active
- 2018-11-11 PL PL18876779.2T patent/PL3706739T3/pl unknown
- 2018-11-11 BR BR112020009173-1A patent/BR112020009173A2/pt not_active Application Discontinuation
- 2018-11-11 LT LTEPPCT/US2018/060232T patent/LT3706739T/lt unknown
- 2018-11-11 SM SM20250022T patent/SMT202500022T1/it unknown
- 2018-11-11 DK DK18876779.2T patent/DK3706739T3/da active
- 2018-11-11 EP EP24199849.1A patent/EP4483956B1/en active Active
- 2018-11-11 SM SM20260156T patent/SMT202600156T1/it unknown
- 2018-11-11 SG SG11202004332XA patent/SG11202004332XA/en unknown
- 2018-11-11 RS RS20241371A patent/RS66277B1/sr unknown
- 2018-11-11 EP EP25216909.9A patent/EP4699619A3/en active Pending
- 2018-11-11 RS RS20260329A patent/RS67956B1/sr unknown
- 2018-11-11 SI SI201831180T patent/SI3706739T1/sl unknown
- 2018-11-11 CA CA3082096A patent/CA3082096A1/en active Pending
- 2018-11-11 IL IL274532A patent/IL274532B2/en unknown
- 2018-11-11 HU HUE18876779A patent/HUE070302T2/hu unknown
- 2018-11-11 FI FIEP24199849.1T patent/FI4483956T3/fi active
- 2018-11-11 FI FIEP18876779.2T patent/FI3706739T3/fi active
- 2018-11-11 AU AU2018364749A patent/AU2018364749C1/en active Active
- 2018-11-11 DK DK24199849.1T patent/DK4483956T3/da active
- 2018-11-11 HR HRP20241675TT patent/HRP20241675T1/hr unknown
- 2018-11-11 US US16/762,165 patent/US20210023061A1/en active Pending
- 2018-11-11 PT PT188767792T patent/PT3706739T/pt unknown
- 2018-11-11 JP JP2020526149A patent/JP7352542B2/ja active Active
- 2018-11-11 EP EP18876779.2A patent/EP3706739B1/en active Active
- 2018-11-11 EP EP25216894.3A patent/EP4696324A3/en active Pending
- 2018-11-11 PT PT241998491T patent/PT4483956T/pt unknown
- 2018-11-11 WO PCT/US2018/060232 patent/WO2019094851A1/en not_active Ceased
- 2018-11-11 CN CN201880073828.6A patent/CN112292127A/zh active Pending
-
2020
- 2020-05-08 PH PH12020550583A patent/PH12020550583A1/en unknown
- 2020-05-11 ZA ZA2020/02626A patent/ZA202002626B/en unknown
- 2020-07-13 MX MX2023012640A patent/MX2023012640A/es unknown
-
2023
- 2023-07-17 US US18/353,850 patent/US20230355592A1/en active Pending
- 2023-07-17 US US18/353,840 patent/US12102618B2/en active Active
- 2023-09-15 JP JP2023149803A patent/JP2023175823A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202600156T1 (it) | Troriluzolo per l’uso nel trattamento dell’atassia spinocerebellare | |
| GB201813876D0 (en) | Treatment | |
| IL276482A (en) | Compounds for pain management | |
| GB201800546D0 (en) | Treatment | |
| EP3697914C0 (en) | VECTORS FOR TREATMENT OF FRIEDREICH'S AAXIA | |
| ZA201907974B (en) | Agent for preventing or treating spinocerebellar ataxia | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| GB201814905D0 (en) | Treatment | |
| GB201807079D0 (en) | Concept 168 | |
| GB201807097D0 (en) | Concept 11 | |
| GB201807104D0 (en) | Concept 30 | |
| GB201807131D0 (en) | Concept 43 | |
| GB201807125D0 (en) | Concept 37 | |
| GB201807126D0 (en) | Concept 364 | |
| GB201807124D0 (en) | Concept 36 | |
| GB201807117D0 (en) | Concept 32 | |
| GB201807084D0 (en) | Concept 33 | |
| GB201807127D0 (en) | Concept 39 | |
| GB201807094D0 (en) | Concept 22 | |
| GB201807083D0 (en) | Concept 29 | |
| GB201807121D0 (en) | Concept 33 | |
| GB201807081D0 (en) | Concept 23 | |
| GB201807130D0 (en) | Concept 42 | |
| GB201807093D0 (en) | Concept 21 | |
| GB201807080D0 (en) | Concept 54 |